MD Anderson Research Highlights for November 30, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a novel HER2-targeted bispecific antibody for several types of cancers, an immunotherapy and PARP-inhibitor combination that may benefit specific tumor molecular subtypes, a comprehensive look at the efficacy of eligibility criteria...
MD Anderson Research Highlights for November 16, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
MD Anderson and Exscientia launch strategic collaboration to leverage AI in developing novel oncology treatments
The University of Texas MD Anderson Cancer Center and Exscientia plc today announced a strategic collaboration to align the drug discovery...
Eyal Gottlieb, Ph.D., to join MD Anderson as Vice President for Research
The University of Texas MD Anderson Cancer Center today announced that Eyal Gottlieb, Ph.D., has been named the institution’s vice president for Research. Gottlieb, an accomplished scientist and leader, will join MD Anderson in January to uphold and expand the institution’s research excellence.
In this role, Gottlieb will oversee laboratory science departments leading innovative discovery and translational research across a variety...
Nanotechnology platform enables immune conversion of cancer cells, sensitizing them to immunotherapy
A team of researchers at The University of Texas MD Anderson Cancer Center has developed a nanotechnology platform that can change the way...
MD Anderson Research Highlights: SITC 2022 Special Edition
ABSTRACTS: 374, 568, 590, 657, 659, 782
The University of Texas MD Anderson Cancer Center’s...
Shorter course of radiation therapy yields comparable results for patients with non-metastatic soft tissue sarcoma
Patients with non-metastatic soft tissue sarcoma (STS) who need pre-operative radiation therapy can safely receive hypofractionated treatment...
MD Anderson Research Highlights for November 3, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
Hormone therapy could lower risk of immunotherapy-associated myocarditis in women
A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center and the University of California San Francisco...